PROCEDURE FOR THE LIVE REGULATION OF THE CONTRACTILITY OF THE CARDIAC MUSCLE.

摘要

Use of a recombinant expression vector consisting of an adeno-associated viral vector (AAV) encoding SERCA2, in the manufacture of a medicament for transducing cardiac myocytes to improve cardiac contractility for the treatment of heart failure, inducing an increase in the speed of systolic contraction or diastolic relaxation in the heart of a patient from pre-transduction levels over a period of at least 4 weeks.